QLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Qualys is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has decent fundamentals and some supportive buying from hedge funds, but the analyst community is mixed to bearish, price targets have been cut broadly, and the current technical setup is only moderately constructive rather than a strong entry. Since you are unwilling to wait for an optimal entry, this is still not the best immediate buy. My direct view: hold and wait for a better setup.
QLYS is trading pre-market around 101.1, slightly above the reported current price of 100.37 and above its pivot at 95.703. MACD histogram is positive at 0.827, which supports short-term upward momentum, but it is positively contracting, so momentum is cooling. RSI at 61.8 is neutral-to-bullish, not overbought, and moving averages are converging, which suggests the trend is improving but not strongly trending yet. Near-term resistance sits at 103.301, then 107.995, so upside from here looks limited unless it breaks resistance cleanly.
Hedge funds are buying aggressively, with reported buying up 44689.22% over the last quarter. Winmill & Co. bought 88,641 shares worth about $9.82 million, a meaningful vote of confidence. The latest quarter showed solid growth, with revenue up 10% year over year and current billings growth of 8%. Analysts also pointed to improving demand for ETM and positive early feedback on QFlex. Options sentiment is bullish, and the stock is trading above key pivot support.
JPMorgan is Underweight, Morgan Stanley is Underweight, and multiple firms moved to Hold or Neutral. William Blair downgraded the stock amid concerns that software names need growth acceleration to escape the AI-disruption penalty box. Growth is durable but not accelerating enough to justify a strong re-rating yet. The stock is also sitting just below near-term resistance, which limits immediate upside.
Latest quarter: Q1 2026. Qualys posted a solid quarter with revenue of $176M, up 10% year over year. Piper Sandler noted a $2M beat and $3M raise, while Canaccord highlighted durable growth and a marginal FY26 raise. Current billings growth was 8%, which is healthy but not the kind of reacceleration bulls want for a sustained valuation expansion. Overall, the quarter was good, but not strong enough to make the stock an obvious long-term buy at this price.
Analyst ratings have turned more cautious recently. Several firms lowered price targets: JPMorgan to $87 and Underweight, Scotiabank to $100 and Sector Perform, Baird to $110 and Neutral, Piper Sandler to $100 and Neutral, Morgan Stanley to $96 and Underweight, and Truist to $85 and Hold. Northland and Canaccord remain more positive, with Northland at Outperform and Canaccord at Buy, but the broader street tone is mixed-to-negative. Wall Street pros see durable fundamentals and good execution, but they are skeptical that growth is accelerating enough to justify a higher multiple right now.
